Titre : Carbonic anhydrase II

Carbonic anhydrase II : Questions médicales fréquentes

Termes MeSH sélectionnés :

Platelet Transfusion
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Carbonic anhydrase II : Questions médicales les plus fréquentes", "headline": "Carbonic anhydrase II : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Carbonic anhydrase II : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-02", "dateModified": "2025-04-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Carbonic anhydrase II" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Carbonic anhydrases", "url": "https://questionsmedicales.fr/mesh/D002256", "about": { "@type": "MedicalCondition", "name": "Carbonic anhydrases", "code": { "@type": "MedicalCode", "code": "D002256", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D08.811.520.241.300.150" } } }, "about": { "@type": "MedicalCondition", "name": "Carbonic anhydrase II", "alternateName": "Carbonic Anhydrase II", "code": { "@type": "MedicalCode", "code": "D024402", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Claudiu T Supuran", "url": "https://questionsmedicales.fr/author/Claudiu%20T%20Supuran", "affiliation": { "@type": "Organization", "name": "Laboratorio di Chimica Bioinorganica, Polo Scientifico Neurofarba Department, Università Degli Studi di Firenze, Room 188, Via della Lastruccia 3, Sesto Fiorentino, 50019 Florence, Italy." } }, { "@type": "Person", "name": "Andrea Angeli", "url": "https://questionsmedicales.fr/author/Andrea%20Angeli", "affiliation": { "@type": "Organization", "name": "Laboratorio di Chimica Bioinorganica, Polo Scientifico Neurofarba Department, Università Degli Studi di Firenze, Room 188, Via della Lastruccia 3, Sesto Fiorentino, 50019 Florence, Italy." } }, { "@type": "Person", "name": "Robert McKenna", "url": "https://questionsmedicales.fr/author/Robert%20McKenna", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Biology, College of Medicine, University of Florida, Gainesville, FL 32610, USA." } }, { "@type": "Person", "name": "Ahmed Al-Harrasi", "url": "https://questionsmedicales.fr/author/Ahmed%20Al-Harrasi", "affiliation": { "@type": "Organization", "name": "University of Nizwa, Chair of Oman's Medicinal Plants and Marine Natural Products, PO Box 33, Birkat Al-Mauz, Nizwa, Oman." } }, { "@type": "Person", "name": "Srabani Taraphder", "url": "https://questionsmedicales.fr/author/Srabani%20Taraphder", "affiliation": { "@type": "Organization", "name": "Department of Chemistry, Indian Institute of Technology, Kharagpur 721302, India." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Platelet Rich Plasma and Adipose-Derived Mesenchymal Stem Cells Mitigate Methotrexate-Induced Nephrotoxicity in Rat via Nrf2/Pparγ/HO-1 and NF-Κb/Keap1/Caspase-3 Signaling Pathways: Oxidative Stress and Apoptosis Interplay.", "datePublished": "2023-04-22", "url": "https://questionsmedicales.fr/article/37235213", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/toxics11050398" } }, { "@type": "ScholarlyArticle", "name": "Association between neutrophil percentage-to-albumin ratio (NPAR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and long-term mortality in community-dwelling adults with heart failure: evidence from US NHANES 2005-2016.", "datePublished": "2023-06-21", "url": "https://questionsmedicales.fr/article/37344786", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12872-023-03316-6" } }, { "@type": "ScholarlyArticle", "name": "Autologous microfragmented adipose tissue and leukocyte-poor platelet-rich plasma combined with hyaluronic acid show comparable clinical outcomes for symptomatic early knee osteoarthritis over a two-year follow-up period: a prospective randomized clinical trial.", "datePublished": "2022-08-23", "url": "https://questionsmedicales.fr/article/35997833", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s00590-022-03356-2" } }, { "@type": "ScholarlyArticle", "name": "The use of recombinant human platelet-derived growth factor-BB in combination with β-tricalcium phosphate and rhPDGF-BB in combination with freeze-dried bone allograft plus barrier in two separate complex infrabony defects with long-term follow-up.", "datePublished": "2022-10-25", "url": "https://questionsmedicales.fr/article/36281628", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cap.10212" } }, { "@type": "ScholarlyArticle", "name": "Clinical evaluation of the combined efficacy of injectable platelet-rich fibrin along with scaling and root planing in the non-surgical periodontal therapy of stage III and grade C periodontitis patients having type 2 diabetes mellitus: A randomized controlled trial.", "datePublished": "2023-09-25", "url": "https://questionsmedicales.fr/article/37749861", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/cap.10266" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Enzymes et coenzymes", "item": "https://questionsmedicales.fr/mesh/D045762" }, { "@type": "ListItem", "position": 3, "name": "Enzymes", "item": "https://questionsmedicales.fr/mesh/D004798" }, { "@type": "ListItem", "position": 4, "name": "Lyases", "item": "https://questionsmedicales.fr/mesh/D008190" }, { "@type": "ListItem", "position": 5, "name": "Carbon-oxygen lyases", "item": "https://questionsmedicales.fr/mesh/D019757" }, { "@type": "ListItem", "position": 6, "name": "Hydro-lyases", "item": "https://questionsmedicales.fr/mesh/D006836" }, { "@type": "ListItem", "position": 7, "name": "Carbonic anhydrases", "item": "https://questionsmedicales.fr/mesh/D002256" }, { "@type": "ListItem", "position": 8, "name": "Carbonic anhydrase II", "item": "https://questionsmedicales.fr/mesh/D024402" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Carbonic anhydrase II - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Carbonic anhydrase II", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Carbonic anhydrase II", "description": "Comment diagnostiquer une déficience en anhydrase carbonique II ?\nQuels tests sont utilisés pour évaluer l'activité de l'enzyme ?\nQuels symptômes peuvent indiquer un problème avec l'enzyme ?\nL'imagerie est-elle utile dans le diagnostic ?\nPeut-on diagnostiquer par biopsie ?", "url": "https://questionsmedicales.fr/mesh/D024402?mesh_terms=Platelet+Transfusion&page=717#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Carbonic anhydrase II", "description": "Quels sont les symptômes d'une déficience en anhydrase carbonique II ?\nY a-t-il des symptômes spécifiques chez les enfants ?\nLes symptômes varient-ils selon l'âge ?\nComment les symptômes évoluent-ils avec le temps ?\nLes symptômes sont-ils similaires à d'autres maladies ?", "url": "https://questionsmedicales.fr/mesh/D024402?mesh_terms=Platelet+Transfusion&page=717#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Carbonic anhydrase II", "description": "Peut-on prévenir la déficience en anhydrase carbonique II ?\nY a-t-il des conseils pour les familles à risque ?\nLes tests prénataux peuvent-ils aider ?\nL'éducation sur la maladie est-elle importante ?\nLes dépistages réguliers sont-ils recommandés ?", "url": "https://questionsmedicales.fr/mesh/D024402?mesh_terms=Platelet+Transfusion&page=717#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Carbonic anhydrase II", "description": "Quels traitements sont disponibles pour la déficience en anhydrase carbonique II ?\nLa thérapie génique est-elle une option ?\nLes médicaments peuvent-ils aider à gérer les symptômes ?\nY a-t-il des traitements non médicamenteux ?\nLes traitements sont-ils efficaces à long terme ?", "url": "https://questionsmedicales.fr/mesh/D024402?mesh_terms=Platelet+Transfusion&page=717#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Carbonic anhydrase II", "description": "Quelles complications peuvent survenir avec cette déficience ?\nLes complications sont-elles réversibles ?\nY a-t-il un risque accru de maladies associées ?\nComment les complications sont-elles surveillées ?\nLes complications affectent-elles la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D024402?mesh_terms=Platelet+Transfusion&page=717#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Carbonic anhydrase II", "description": "Quels sont les facteurs de risque pour cette déficience ?\nL'environnement joue-t-il un rôle ?\nLes facteurs de risque sont-ils modifiables ?\nLes femmes sont-elles plus à risque ?\nLes personnes âgées sont-elles plus à risque ?", "url": "https://questionsmedicales.fr/mesh/D024402?mesh_terms=Platelet+Transfusion&page=717#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en anhydrase carbonique II ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques et des analyses sanguines peuvent confirmer la déficience." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité de l'enzyme ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests enzymatiques mesurant l'activité de l'anhydrase carbonique dans le sang sont utilisés." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec l'enzyme ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des troubles respiratoires ou des déséquilibres acido-basiques peuvent survenir." } }, { "@type": "Question", "name": "L'imagerie est-elle utile dans le diagnostic ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie peut aider à évaluer les complications, mais n'est pas spécifique au diagnostic." } }, { "@type": "Question", "name": "Peut-on diagnostiquer par biopsie ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Une biopsie peut être réalisée pour évaluer des tissus affectés, mais ce n'est pas courant." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une déficience en anhydrase carbonique II ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des troubles respiratoires, des maux de tête et des troubles neurologiques." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques chez les enfants ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les enfants peuvent présenter des retards de développement et des problèmes respiratoires fréquents." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon l'âge ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent être plus graves chez les jeunes enfants que chez les adultes." } }, { "@type": "Question", "name": "Comment les symptômes évoluent-ils avec le temps ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent s'aggraver avec le temps si la condition n'est pas traitée." } }, { "@type": "Question", "name": "Les symptômes sont-ils similaires à d'autres maladies ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être confondus avec d'autres troubles respiratoires ou métaboliques." } }, { "@type": "Question", "name": "Peut-on prévenir la déficience en anhydrase carbonique II ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Étant une condition génétique, la prévention n'est pas possible, mais un suivi médical est crucial." } }, { "@type": "Question", "name": "Y a-t-il des conseils pour les familles à risque ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les familles à risque devraient consulter un généticien pour des conseils et un suivi approprié." } }, { "@type": "Question", "name": "Les tests prénataux peuvent-ils aider ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des tests prénataux peuvent identifier des anomalies génétiques liées à cette condition." } }, { "@type": "Question", "name": "L'éducation sur la maladie est-elle importante ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation des patients et des familles est essentielle pour une gestion efficace." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils recommandés ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des dépistages réguliers peuvent aider à identifier les symptômes précoces chez les individus à risque." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour la déficience en anhydrase carbonique II ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement peut inclure des suppléments de bicarbonate et des médicaments pour gérer les symptômes." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche, mais pas encore une option standard pour cette condition." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils aider à gérer les symptômes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des médicaments comme les inhibiteurs de l'anhydrase carbonique peuvent être prescrits." } }, { "@type": "Question", "name": "Y a-t-il des traitements non médicamenteux ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des modifications du mode de vie, comme une alimentation équilibrée, peuvent aider." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces à long terme ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements peuvent aider à gérer les symptômes, mais ne guérissent pas la déficience." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec cette déficience ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles respiratoires graves et des déséquilibres électrolytiques." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes sans traitement." } }, { "@type": "Question", "name": "Y a-t-il un risque accru de maladies associées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients peuvent avoir un risque accru de maladies respiratoires et métaboliques." } }, { "@type": "Question", "name": "Comment les complications sont-elles surveillées ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Les complications sont surveillées par des examens réguliers et des tests de laboratoire." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement affecter la qualité de vie des patients." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour cette déficience ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs de risque incluent des antécédents familiaux et des mutations génétiques spécifiques." } }, { "@type": "Question", "name": "L'environnement joue-t-il un rôle ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "L'environnement n'est pas un facteur de risque direct, mais peut influencer la gravité des symptômes." } }, { "@type": "Question", "name": "Les facteurs de risque sont-ils modifiables ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs génétiques ne sont pas modifiables, mais un mode de vie sain peut aider à gérer les symptômes." } }, { "@type": "Question", "name": "Les femmes sont-elles plus à risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Le risque est généralement égal entre les sexes, mais certaines mutations peuvent avoir des effets différents." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "L'âge n'est pas un facteur de risque direct, mais les symptômes peuvent être plus prononcés chez les personnes âgées." } } ] } ] }

Sources (7169 au total)

Platelet Rich Plasma and Adipose-Derived Mesenchymal Stem Cells Mitigate Methotrexate-Induced Nephrotoxicity in Rat via Nrf2/Pparγ/HO-1 and NF-Κb/Keap1/Caspase-3 Signaling Pathways: Oxidative Stress and Apoptosis Interplay.

the nephrotoxicity of methotrexate (MTX) is observed in high-dose therapy. Moreover, low-dose MTX therapy for rheumatic diseases is debatable and claimed to cause renal impairment. This study aimed at... Forty-two male Wistar rats were used, 10 rats were donors of AD-MSCs and PRP, 8 rats served as control, and the remaining rats were subjected to induction of nephrotoxicity by MTX intraperitoneal inje... there was significant tubular degeneration, glomerulosclerosis, fibrosis, decreased renal index, along with increased levels of urea and creatinine in the MTX group compared to the control group. Immu... repeated administration of low-dose MTX resulted in massive renal tissue toxicity and deterioration of renal function in rats which proved to be attenuated by PRP and AD-MSCs through their anti-inflam...

Association between neutrophil percentage-to-albumin ratio (NPAR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and long-term mortality in community-dwelling adults with heart failure: evidence from US NHANES 2005-2016.

Heart failure (HF) continues to be the major cause of hospitalizations. Despite numerous significant therapeutic progress, the mortality rate of HF is still high. This longitudianl cohort study aimed ... Adults aged 20 and older with HF in the US National Health and Nutrition Examination Survey (NHANES) database 2005-2016 were included and were followed through the end of 2019. Univariate and multivar... A total of 1,207 subjects with HF were included, representing a population of 4,606,246 adults in the US. The median follow-up duration was 66.0 months. After adjustment, the highest quartile of NPAR ... In conclusion, elevated NPAR and NLR but not PLR are independently associated with increased all-cause mortality among community-dwelling individuals with HF. However, the predictive performance of NP...

Autologous microfragmented adipose tissue and leukocyte-poor platelet-rich plasma combined with hyaluronic acid show comparable clinical outcomes for symptomatic early knee osteoarthritis over a two-year follow-up period: a prospective randomized clinical trial.

The purpose of this prospective randomized clinical trial is to compare the clinical outcomes of three injections of leucocyte-poor platelet-rich plasma (LP-PRP) and hyaluronic acid (HA) to a single d... Eighty symptomatic knees in fifty patients (mean age: 62.38 ± 11.88 years) with Kellgren-Lawrence grade 0 to 2 osteoarthritis were non blinded, randomly allocated into two equal groups. Group 1 consis... Both groups had significant clinical and functional improvement at 6, 12, and 24 months (p < 0.05). Comparing the two groups, the AMAT groups showed significantly higher pre-operative Marx score (3.35... AMAT did not show significant superior clinical improvement compared with three LP-PRP combined with HA injections in terms of functional improvement at different follow-up points. Both procedures wer... Level I-Prospective Randomized Clinical Trial....

The use of recombinant human platelet-derived growth factor-BB in combination with β-tricalcium phosphate and rhPDGF-BB in combination with freeze-dried bone allograft plus barrier in two separate complex infrabony defects with long-term follow-up.

Reports from a large-scale, prospective, masked, randomized controlled clinical trial demonstrated gain in attachment level, linear bone gain, and percentage bone fill in infrabony defects treated wit... Two complex infrabony defect cases are presented in this report: one using rhPDGF-BB with β-TCP and the other using rhPDGF-BB with freeze-dried bone allograft (FDBA) and a resorbable barrier membrane.... Both cases demonstrate significant gains in clinical attachment levels as well as bone-like fill as observed radiographically and at reentry.... These case reports of combining rhPDGF-BB with β-TCP or with FDBA and a barrier membrane support the literature showing improvement in attachment levels and demonstrating bone fill in complex infrabon...

Clinical evaluation of the combined efficacy of injectable platelet-rich fibrin along with scaling and root planing in the non-surgical periodontal therapy of stage III and grade C periodontitis patients having type 2 diabetes mellitus: A randomized controlled trial.

This randomized controlled trial was aimed to evaluate the combined efficacy of injectable platelet-rich fibrin (i-PRF) and scaling and root planing (SRP) in type 2 diabetes mellitus subjects having p... Twenty-six Stage III, grade C periodontitis subjects (HbA1c > 7) were recruited in this split-mouth study. Following SRP, the test sites received subgingival application of i-PRF, while the control si... Twenty-three participants completed the course of research. The Friedman test followed by Dunn's post hoc test, revealed significant improvement in all the clinical parameters from baseline to 3 and 6... Question: To find the combined efficacy of injectable platelet-rich fibrin (i-PRF) along with scaling and root planing (SRP) in the management of periodontal pockets of Stage III and Grade C periodont... All of the treated sites showed satisfactory healing. Both the treatment modalities (i-PRF + SRP and Saline + SRP) were effective in the treatment of periodontal pockets. At 3 and 6 months, there were...

Preoperative Neutrophil-Lymphocyte Ratio (NLR)-Binding Fibrinogen-Albumin Ratio (FAR) Is Superior to Platelet-Lymphocyte Ratio (PLR)-Binding Fibrinogen-Albumin Ratio (FAR) and Lymphocyte-Monocyte (LMR)-Binding Fibrinogen-Albumin Ratio (FAR) as Predictors of Survival in Surgical Patients with Colorectal Adenocarcinoma.

BACKGROUND Studies have revealed that having systemic inflammation is linked to worse survival rates across a range of malignancies. This study aimed to evaluate the predictive significance of neutrop...

Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology.

TACE plays a pivotal role in hepatocellular carcinoma, from disease control to downstaging and bridging to liver transplant. Response to TACE is a surrogate marker of tumor aggressive biology, with ma...